Adam Gerstenecker1, Karen Meneses2,3, Kevin Duff4, John B Fiveash2,5, Daniel C Marson1, Kristen L Triebel1,2. 1. Department of Neurology, Division of Neuropsychology, UAB, Birmingham, Alabama. 2. Comprehensive Cancer Center, UAB, Birmingham, Alabama. 3. School of Nursing, UAB, Birmingham, Alabama. 4. Department of Neurology, University of Utah, Salt Lake City, Utah. 5. Department of Radiation Oncology, UAB, Birmingham, Alabama.
Abstract
BACKGROUND: Medical decision-making capacity is a higher-order functional skill that refers to a patient's ability to make informed, sound decisions related to care and treatment. In a medical context, understanding is the most cognitively demanding consent standard and refers to a patient's ability to comprehend information to the extent that informed decisions can be made. METHODS: The association between reasoning and cognition was examined using data from 41 patients with diagnosed brain metastasis. All diagnoses were made by a board-certified radiation oncologist and were verified histologically. In total, 41 demographically matched, cognitively healthy controls were also included to aid in classifying patients with brain metastasis according to reasoning status (ie, intact or impaired). RESULTS: Results indicate that measures of simple attention, verbal fluency, verbal memory, processing speed, and executive functioning were all associated with understanding, and that verbal memory and phonemic fluency were the primary cognitive predictors. Using these two primary predictors, equations can be constructed to predict the ability to understand treatment decisions in patients with brain metastasis. CONCLUSIONS: Although preliminary, these data demonstrate how cognitive measures can estimate understanding as it relates to medical decision-making capacities in these patients. Clinically, these findings suggest that poor verbal memory and expressive language function could serve as "red flags" for reduced consent capacity in this patient population, thus signaling that a more comprehensive medical decision-making capacity evaluation is warranted.
BACKGROUND: Medical decision-making capacity is a higher-order functional skill that refers to a patient's ability to make informed, sound decisions related to care and treatment. In a medical context, understanding is the most cognitively demanding consent standard and refers to a patient's ability to comprehend information to the extent that informed decisions can be made. METHODS: The association between reasoning and cognition was examined using data from 41 patients with diagnosed brain metastasis. All diagnoses were made by a board-certified radiation oncologist and were verified histologically. In total, 41 demographically matched, cognitively healthy controls were also included to aid in classifying patients with brain metastasis according to reasoning status (ie, intact or impaired). RESULTS: Results indicate that measures of simple attention, verbal fluency, verbal memory, processing speed, and executive functioning were all associated with understanding, and that verbal memory and phonemic fluency were the primary cognitive predictors. Using these two primary predictors, equations can be constructed to predict the ability to understand treatment decisions in patients with brain metastasis. CONCLUSIONS: Although preliminary, these data demonstrate how cognitive measures can estimate understanding as it relates to medical decision-making capacities in these patients. Clinically, these findings suggest that poor verbal memory and expressive language function could serve as "red flags" for reduced consent capacity in this patient population, thus signaling that a more comprehensive medical decision-making capacity evaluation is warranted.
Authors: Kristen L Triebel; Adam Gerstenecker; Karen Meneses; John B Fiveash; Christina A Meyers; Gary Cutter; Daniel C Marson; Roy C Martin; Amanda Eakin; Olivia Watts; Louis B Nabors Journal: Psychooncology Date: 2015-01-23 Impact factor: 3.894
Authors: O Okonkwo; H R Griffith; K Belue; S Lanza; E Y Zamrini; L E Harrell; J C Brockington; D Clark; R Raman; D C Marson Journal: Neurology Date: 2007-10-09 Impact factor: 9.910
Authors: Roy C Martin; Ozioma C Okonkwo; Joni Hill; H Randall Griffith; Kristen Triebel; Alfred Bartolucci; Anthony P Nicholas; Ray L Watts; Natividad Stover; Lindy E Harrell; David Clark; Daniel C Marson Journal: Mov Disord Date: 2008-10-15 Impact factor: 10.338
Authors: Adam Gerstenecker; Kevin Duff; Karen Meneses; John B Fiveash; Louis B Nabors; Kristen L Triebel Journal: J Int Neuropsychol Soc Date: 2015-07-07 Impact factor: 2.892
Authors: Eli L Diamond; David Russell; Maria Kryza-Lacombe; Kathryn H Bowles; Allison J Applebaum; Jeanne Dennis; Lisa M DeAngelis; Holly G Prigerson Journal: Neuro Oncol Date: 2015-08-09 Impact factor: 12.300
Authors: Andrea Pace; Johan A F Koekkoek; Martin J van den Bent; Helen J Bulbeck; Jane Fleming; Robin Grant; Heidrun Golla; Roger Henriksson; Simon Kerrigan; Christine Marosi; Ingela Oberg; Stefan Oberndorfer; Kathy Oliver; H Roeline W Pasman; Emilie Le Rhun; Alasdair G Rooney; Roberta Rudà; Simone Veronese; Tobias Walbert; Michael Weller; Wolfgang Wick; Martin J B Taphoorn; Linda Dirven Journal: Neurooncol Pract Date: 2020-07-16
Authors: Will Hewins; Karolis Zienius; James L Rogers; Simon Kerrigan; Mark Bernstein; Robin Grant Journal: Curr Oncol Rep Date: 2019-05-02 Impact factor: 5.075